drugset / Trial / NCT07104643
Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the safety, and preliminary antitumor activity of TYK-00540 combined with Enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
Timeline
- Start
- 2025-08
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | TYK-00540 | Unknown | 20 mg | Oral |
| Subject | TYK-00540 | Unknown | 30 mg | Oral |